Skip to content
buyModerate cluster of 2

Earl M Collier Jr bought $28k of CAPR

director at CAPRICOR THERAPEUTICS, INC.. 10,000 shares at an average of $2.83, traded Oct 10, 2023, filed Oct 12, 2023.

Conviction score
56
Value
$28k
10,000 shares
Holdings after
26,856
+59% from before
From 52-week low
+3%
low $2.78, close $2.85
From 52-week high
-64%
high $7.85, as of Oct 10, 2023

Score components

  • Role
    Director
    +15
  • Trade size
    $28k at market
    +5
  • Relative to holdings
    Holdings up 59%
    +10
  • Price context
    3% above the 52-week low; 64% below the 52-week high
    +18
  • Cluster
    2 insiders buying within 14 days
    +8
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -1.1%, 3m +62.5%, 6m +120.1%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

CAPROct 9, 2026 · close 7.83
Since filing Oct 12, 2023: +176.7%SPY +86.0% · excess +90.6%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001415889-23-014099, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Oct 10, 2023POpen-market purchase
Common Stock
+10,000$2.83$28k26,856Oct 12, 2023

Related signals

Other insiders at CAPRICOR THERAPEUTICS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
36Weak
CAPRsell 210b5-1
CAPRICOR THERAPEUTICS, INC.
Anthony Bergmann
CHIEF FINANCIAL OFFICER
$732k
24,100 shares
-68%
19Weak
CAPRsell 210b5-1
CAPRICOR THERAPEUTICS, INC.
Karen Krasney
EVP, GENERAL COUNSEL
$732k
24,100 shares
-44%
0Weak
CAPRsell 210b5-1
CAPRICOR THERAPEUTICS, INC.
Anthony Bergmann
CHIEF FINANCIAL OFFICER
$27k
900 shares
-8%
0Weak
CAPRsell 210b5-1
CAPRICOR THERAPEUTICS, INC.
Karen Krasney
EVP, GENERAL COUNSEL
$27k
900 shares
-3%
37Weak
CAPRsell 210b5-1
CAPRICOR THERAPEUTICS, INC.
Anthony Bergmann
CHIEF FINANCIAL OFFICER
$793k
25,000 shares
-75%
20Weak
CAPRsell 210b5-1
CAPRICOR THERAPEUTICS, INC.
Karen Krasney
EVP, GENERAL COUNSEL
$793k
25,000 shares
-45%
28Weak
CAPRsell 310b5-1
CAPRICOR THERAPEUTICS, INC.
Karimah Es Sabar
director
$241k
7,529 shares
-100%
44Moderate
CAPRsell 310b5-1
CAPRICOR THERAPEUTICS, INC.
Anthony Bergmann
CHIEF FINANCIAL OFFICER
$753k
25,000 shares
-75%
27Weak
CAPRsell 310b5-1
CAPRICOR THERAPEUTICS, INC.
Karen Krasney
EVP, GENERAL COUNSEL
$753k
25,000 shares
-45%
40Moderate
CAPRsell 310b5-1
CAPRICOR THERAPEUTICS, INC.
Karimah Es Sabar
director
$3.5M
115,000 shares
-188%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Earl M Collier Jr bought $28k of CAPR | InsiderTell